MX2018010427A - Formas solidas de un inhibidor de tienopirimidindiona acetil coa carboxilasa y metodos para su produccion. - Google Patents

Formas solidas de un inhibidor de tienopirimidindiona acetil coa carboxilasa y metodos para su produccion.

Info

Publication number
MX2018010427A
MX2018010427A MX2018010427A MX2018010427A MX2018010427A MX 2018010427 A MX2018010427 A MX 2018010427A MX 2018010427 A MX2018010427 A MX 2018010427A MX 2018010427 A MX2018010427 A MX 2018010427A MX 2018010427 A MX2018010427 A MX 2018010427A
Authority
MX
Mexico
Prior art keywords
methods
solid forms
production
acc inhibitor
thienopyrimidinedione
Prior art date
Application number
MX2018010427A
Other languages
English (en)
Inventor
C Harriman Geraldine
Morrison Henry
Alexander Katy
C Amedio John Jr
Calimsiz Selcuk
Geier Michael
Hu Sijun
P Lawson Jon
Sabourin Kyle
Varghese Vimal
Arvind Varia Kunal
Yang Xiaowei
E Scott Mark
Wang Xiaotian
Original Assignee
Gilead Apollo Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Apollo Llc filed Critical Gilead Apollo Llc
Publication of MX2018010427A publication Critical patent/MX2018010427A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/001—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by metabolizing one of the enantiomers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

La presente invención proporciona formas sólidas de compuestos útiles como inhibidores de la acetil CoA carboxilasa (ACC), sus composiciones, sus métodos de producción y métodos de uso de los mismos en el tratamiento de enfermedades mediadas por la ACC.
MX2018010427A 2016-03-02 2017-03-01 Formas solidas de un inhibidor de tienopirimidindiona acetil coa carboxilasa y metodos para su produccion. MX2018010427A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662302755P 2016-03-02 2016-03-02
US201662303237P 2016-03-03 2016-03-03
PCT/US2017/020271 WO2017151816A1 (en) 2016-03-02 2017-03-01 Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof

Publications (1)

Publication Number Publication Date
MX2018010427A true MX2018010427A (es) 2019-03-06

Family

ID=58347936

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010427A MX2018010427A (es) 2016-03-02 2017-03-01 Formas solidas de un inhibidor de tienopirimidindiona acetil coa carboxilasa y metodos para su produccion.

Country Status (13)

Country Link
US (4) US10183951B2 (es)
EP (2) EP3423456B1 (es)
JP (3) JP6944462B2 (es)
KR (2) KR20230035692A (es)
CN (2) CN112920200A (es)
AU (3) AU2017226267B2 (es)
BR (1) BR112018067408A2 (es)
CA (4) CA3172549A1 (es)
IL (1) IL261255A (es)
MX (1) MX2018010427A (es)
SG (1) SG11201807077RA (es)
TW (3) TWI788281B (es)
WO (1) WO2017151816A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI491606B (zh) 2009-07-13 2015-07-11 Gilead Sciences Inc 調節細胞凋亡信號之激酶的抑制劑
SI3329919T1 (sl) 2011-11-11 2020-02-28 Gilead Apollo, Llc Inhibitorji ACC in njihove uporabe
SI3191470T1 (sl) 2015-07-06 2019-04-30 Gilead Sciences, Inc. Modulatorji COT in postopki njihove uporabe
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
EA201890910A1 (ru) 2015-11-25 2018-11-30 Джилид Аполло, Ллс ФУНГИЦИДНЫЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 2,4-ДИОКСО-1,4-ДИГИДРОТИЕНО[2,3-d]ПИРИМИДИНА
CN108349995B (zh) 2015-11-25 2021-08-03 吉利德阿波罗公司 吡唑acc抑制剂及其用途
MX2018006288A (es) 2015-11-25 2018-09-07 Gilead Apollo Llc Inhibidores de acc tipo ester y usos de los mismos.
TWI788281B (zh) 2016-03-02 2023-01-01 美商基利阿波羅有限責任公司 噻吩并嘧啶二酮acc抑制劑之固體型式及其製造方法
CA3053956C (en) * 2017-03-03 2024-04-23 Gilead Sciences, Inc. Processes for preparing acc inhibitors and solid forms thereof
CN110461328A (zh) 2017-03-28 2019-11-15 吉利德科学公司 治疗肝疾病的治疗组合
JP7067725B2 (ja) * 2017-07-17 2022-05-16 ナンジン ルイジエ ファーマテック カンパニー， リミテッド Ａｃｃ阻害剤としての新規な化合物およびそれらの使用
KR20190036705A (ko) * 2017-09-28 2019-04-05 한미약품 주식회사 (2r)-2-(2-메톡시페닐)-2-(옥산-4-일옥시)에탄-1-올 화합물의 신규 제조방법 및 이에 사용되는 중간체
TWI814744B (zh) 2017-10-06 2023-09-11 美商基利科學股份有限公司 包含acc抑制劑之組合療法
CN109810085B (zh) * 2019-04-19 2019-07-19 上海皓元生物医药科技有限公司 Acc抑制剂及其中间体的制备方法
TW202235416A (zh) 2019-06-14 2022-09-16 美商基利科學股份有限公司 Cot 調節劑及其使用方法
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
JP2022548617A (ja) 2019-09-19 2022-11-21 ノバルティス アーゲー Ｆｘｒアゴニストを含む処置
CN112574253B (zh) * 2019-09-29 2021-08-27 上海喀露蓝科技有限公司 磷酸或磷酸酯类衍生物、其制备方法及其在医药上的用途
CN110746439B (zh) * 2019-10-18 2020-10-30 南京瑞捷医药科技有限公司 一种噻吩并嘧啶二酮化合物的制备方法
CN112778325A (zh) * 2019-11-07 2021-05-11 南京瑞捷医药科技有限公司 一种acc抑制剂及其用途
KR20220101137A (ko) 2019-11-15 2022-07-19 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도
WO2021110138A1 (zh) * 2019-12-05 2021-06-10 漳州片仔癀药业股份有限公司 噻吩并[2,3-c]哒嗪-4(1H)-酮类化合物的晶型及其制备方法和应用
US11578081B1 (en) 2019-12-05 2023-02-14 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. Crystal form as inhibitor of ACC1 and ACC2, and preparation method therefor and use thereof
AU2021249010A1 (en) 2020-03-30 2022-10-06 Gilead Sciences, Inc. Solid forms of (S)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
CN115397824A (zh) 2020-04-02 2022-11-25 吉利德科学公司 用于制备cot抑制剂化合物的方法
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
JP2023529369A (ja) 2020-06-03 2023-07-10 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニスト及びそれらの使用
CA3183097A1 (en) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
WO2022192428A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
AU2022252182A1 (en) 2021-03-29 2023-09-28 Gilead Sciences, Inc. Khk inhibitors
TWI818538B (zh) 2021-05-11 2023-10-11 美商基利科學股份有限公司 Ｌｐａ受體拮抗劑及其用途
WO2022241023A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
TW202304435A (zh) 2021-06-04 2023-02-01 美商基利科學股份有限公司 治療ｎａｓｈ之方法
TW202311256A (zh) 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑
KR102309616B1 (ko) 2021-07-27 2021-10-05 최금실 호호바오일을 포함하는 피부 재생 및 피부 보습용 화장료 조성물 및 이의 제조방법
KR102337422B1 (ko) 2021-07-27 2021-12-08 (주)최금실 호호바오일을 포함하는 피부진정 및 트러블 개선용 화장료 조성물 및 이의 제조방법
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670560A (en) 1986-04-28 1987-06-02 Ortho Pharmaceutical Corporation Thienopyrimidine-2,4-dione derivatives and intermediates thereof
JPH02225485A (ja) 1989-02-27 1990-09-07 Taiho Yakuhin Kogyo Kk チエノピリミジン―３―酢酸誘導体
WO1997007119A1 (en) 1994-08-26 1997-02-27 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use
TW276256B (es) 1993-08-26 1996-05-21 Takeda Pharm Industry Co Ltd
JP3811196B2 (ja) 1993-08-26 2006-08-16 武田薬品工業株式会社 エンドセリン拮抗剤、チエノピリミジン誘導体およびその製造法
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JPH09110873A (ja) 1995-08-17 1997-04-28 Takeda Chem Ind Ltd チエノピリミジン誘導体、その製造法および用途
JP2007302703A (ja) 1996-04-30 2007-11-22 Takeda Chem Ind Ltd 医薬組成物
AU2407997A (en) 1996-04-30 1997-11-19 Takeda Chemical Industries Ltd. Combined use of gnrh agonist and antagonist
US6984644B2 (en) 1997-05-28 2006-01-10 Astrazeneca Ab Treatment of skin disorders using thieno[2,3-D]pyrimidinediones
SE9702001D0 (sv) 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
DE19754082A1 (de) 1997-12-05 1999-06-10 Knoll Ag Methode zur Bekämpfung der Fettleibigkeit
DE60024604T2 (de) 1999-04-09 2006-08-24 Cell Therapeutics, Inc., Seattle Xanthinderivate und analoge als zellsignalisierung inhibitoren
EP1370562A1 (en) 2001-02-14 2003-12-17 Warner-Lambert Company LLC Thieno[2,3-d]pyrimidindione derivatives as matrix metalloproteinase inhibitors
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
CN1642599A (zh) 2002-02-27 2005-07-20 辉瑞产品公司 Acc抑制剂
AU2003253165A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
EP1585392B1 (en) 2003-01-06 2009-03-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Herbicides inhibiting the action of plant acetyl-coa carboxylase for use as pesticides.
AU2004207706B2 (en) 2003-01-29 2010-03-04 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
US7947691B2 (en) 2004-07-21 2011-05-24 Athersys, Inc. Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof
US20070208040A1 (en) 2006-03-02 2007-09-06 Elfatih Elzein A2a adenosine receptor antagonists
EP2253630A1 (en) 2007-05-21 2010-11-24 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
AU2009259839A1 (en) 2008-06-20 2009-12-23 Kinemed, Inc. Compositions for the treatment of fibrotic diseases or conditions
JP5535931B2 (ja) 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
US20100113473A1 (en) 2008-10-30 2010-05-06 Player Mark R Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor
ME01558B (me) 2009-12-29 2014-04-20 Poxel TIENO [2, 3-B] PIRIDINDION AMPK AKTIVATORI l NJIHOVE TERAPEUTSKE UPOTREBE
WO2012090219A2 (en) 2010-12-31 2012-07-05 Jubilant Biosys Ltd. Thiazole compounds useful as acetyl-coa carboxylase (acc) inhibitors
SI3329919T1 (sl) 2011-11-11 2020-02-28 Gilead Apollo, Llc Inhibitorji ACC in njihove uporabe
EP2815219B1 (en) 2012-02-15 2021-04-07 Robert Bosch GmbH Pressure sensor with doped electrode
JP5842804B2 (ja) * 2012-12-28 2016-01-13 カシオ計算機株式会社 表示端末装置及びプログラム
CA2911926A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
WO2014182950A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
WO2015007451A1 (en) 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
SG11201705361PA (en) 2015-01-09 2017-08-30 Gilead Apollo Llc Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
AR106472A1 (es) * 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
MX2018006288A (es) 2015-11-25 2018-09-07 Gilead Apollo Llc Inhibidores de acc tipo ester y usos de los mismos.
EA201890910A1 (ru) 2015-11-25 2018-11-30 Джилид Аполло, Ллс ФУНГИЦИДНЫЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 2,4-ДИОКСО-1,4-ДИГИДРОТИЕНО[2,3-d]ПИРИМИДИНА
AU2016361428A1 (en) 2015-11-25 2018-05-24 Gilead Apollo, Llc Triazole ACC inhibitors and uses thereof
CN108349995B (zh) * 2015-11-25 2021-08-03 吉利德阿波罗公司 吡唑acc抑制剂及其用途
TWI788281B (zh) 2016-03-02 2023-01-01 美商基利阿波羅有限責任公司 噻吩并嘧啶二酮acc抑制劑之固體型式及其製造方法
KR102577824B1 (ko) 2017-01-22 2023-09-13 선샤인 레이크 파르마 컴퍼니 리미티드 티에노피리미딘 유도체 및 의약에서 이의 용도
KR20190036705A (ko) 2017-09-28 2019-04-05 한미약품 주식회사 (2r)-2-(2-메톡시페닐)-2-(옥산-4-일옥시)에탄-1-올 화합물의 신규 제조방법 및 이에 사용되는 중간체

Also Published As

Publication number Publication date
KR102622161B1 (ko) 2024-01-09
CA3155220C (en) 2024-01-16
CA3172549A1 (en) 2017-09-08
US11104687B2 (en) 2021-08-31
TWI818828B (zh) 2023-10-11
IL261255A (en) 2018-10-31
US20220064181A1 (en) 2022-03-03
AU2017226267A1 (en) 2018-09-06
TW202330543A (zh) 2023-08-01
AU2017226267B2 (en) 2021-06-24
CN108699078A (zh) 2018-10-23
JP6944462B2 (ja) 2021-10-06
AU2021209149B2 (en) 2023-04-20
CN112920200A (zh) 2021-06-08
CA3155220A1 (en) 2017-09-08
US10487090B2 (en) 2019-11-26
TW202400605A (zh) 2024-01-01
AU2023206094A1 (en) 2023-08-10
US10183951B2 (en) 2019-01-22
KR20180114937A (ko) 2018-10-19
JP7356564B2 (ja) 2023-10-04
US20200148699A1 (en) 2020-05-14
SG11201807077RA (en) 2018-09-27
US20190225623A1 (en) 2019-07-25
WO2017151816A1 (en) 2017-09-08
US20170267690A1 (en) 2017-09-21
BR112018067408A2 (pt) 2018-12-26
KR20230035692A (ko) 2023-03-14
EP4364795A2 (en) 2024-05-08
US11912718B2 (en) 2024-02-27
JP2023010977A (ja) 2023-01-20
JP2019507160A (ja) 2019-03-14
EP3423456C0 (en) 2023-12-27
TWI788281B (zh) 2023-01-01
JP2021185206A (ja) 2021-12-09
CA3015526A1 (en) 2017-09-08
EP3423456A1 (en) 2019-01-09
JP7184988B2 (ja) 2022-12-06
EP3423456B1 (en) 2023-12-27
AU2021209149A1 (en) 2021-08-19
CA3015526C (en) 2022-10-04
CA3220447A1 (en) 2017-09-08
TW201738247A (zh) 2017-11-01

Similar Documents

Publication Publication Date Title
MX2018010427A (es) Formas solidas de un inhibidor de tienopirimidindiona acetil coa carboxilasa y metodos para su produccion.
MX2018005292A (es) Inhibidores de acc y usos de los mismos.
MX2018006288A (es) Inhibidores de acc tipo ester y usos de los mismos.
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
MX2015015421A (es) Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
MX2015015417A (es) Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
PH12016501388A1 (en) Heteroaryls and uses thereof
EA201691134A1 (ru) Новые ингибиторы глутаминазы
CA2983453A1 (en) Naphthyridine compounds as jak kinase inhibitors
PH12017501669A1 (en) Alpha-cinnamide compounds and compositions as hdac8 inhibitors
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
PH12015502248B1 (en) 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
PH12018500409A1 (en) New bicyclic compounds as dual atx/ca inhibitors
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2020006434A (es) Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
EP4234552A3 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
MX2020006436A (es) Compuestos inhibidores del blanco mecanistico de rapamicina (mtor).